Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Early European TAVI registry data unveiled

The 1-month follow-up results of the Transcatheter Valve Treatment Sentinel Pilot Registry have provided data on factors associated with transcatheter aortic valve implantation, as well as short term outcomes, in Europe.

30 Aug 2012

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).

29 Aug 2012

Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at ERS Annual Congress

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM therapeutic, the first treatment developed utilizing its iSPERSE inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.

28 Aug 2012

Women with severe aortic stenosis less likely to die following TAVI

Women with severe aortic stenosis are 40% less likely to die after transcatheter aortic valve implantation (TAVI) than men, reveals the latest data from the largest study to date of gender differences in outcomes after TAVI.

27 Aug 2012

Study explores gender-related differences in patients hospitalized for acute heart failure

Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece.

27 Aug 2012

Belly fat linked with increased risk of cardiovascular death in normal weight individuals

Normal weight individuals who carry weight concentrated in their belly have a higher death risk than obese individuals, according to research presented at ESC Congress 2012.

27 Aug 2012

New data from Boehringer Ingelheim and Pfizer's tiotropium clinical studies on asthma, COPD

New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for patients with Chronic Obstructive Pulmonary Disease (COPD).

27 Aug 2012

Study helps explain how human airways clear sticky mucus out of the lungs

A runny nose and a wet cough caused by a cold or an allergy may not feel very good. But human airways rely on sticky mucus to expel foreign matter, including toxic and infectious agents, from the body.

24 Aug 2012

Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases

Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.

17 Aug 2012

Malignant mesothelioma diagnosis with an E-nose: an interview with Associate Professor Deborah Yates, UNSW

Malignant mesothelioma is a rare tumor of the pleura which is the lining of the inside of the chest wall. It is highly linked with asbestos exposure.

16 Aug 2012

Study to test how osteopathic treatment helps patients with COPD

Researchers at Michigan State University are working to show how a noninvasive, drug-free form of hands-on medical care can help patients with chronic obstructive pulmonary disease improve their breathing.

15 Aug 2012

Be alert for arrhythmias in new bronchodilator patients, researchers say

Chronic obstructive pulmonary disease patients should be monitored for the onset of arrhythmia when they begin bronchodilator therapy, say the authors of a Canadian study.

14 Aug 2012

Tai Chi improves health and quality of life for COPD sufferers

A new University of Sydney study has found Tai Chi can be an effective form of exercise therapy for people with chronic obstructive pulmonary disease (COPD), improving exercise capacity and quality of life.

14 Aug 2012

Study signals biomarker hope for monitoring COPD

The biomarkers desmosines and C-reactive protein could be used to assess disease severity in chronic obstructive pulmonary disease, show the results of a Swedish study.

7 Aug 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Healthcare-associated pneumonia management could be improved

Although healthcare-associated pneumonia is common among patients treated in internal medicine departments and linked to poor outcomes, rates of testing and adherence to therapeutic guidelines are low, say Spanish investigators.

30 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Hypoxic lung environment increases HIF-2a tumor growth signaling

In addition to the well-known risk factor of smoking, chronic obstructive pulmonary disease (COPD) increases lung cancer risk.

25 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012